arrow
A

Aimee D Shu

palo alto networks
H指数:12
被引数:511

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Palopegteriparatide in Adults With Hypoparathyroidism: 3.5-Year Results From the Phase 3 PaTHway Trial

帕洛肽端降钙素在成人低甲状旁腺功能减退症中的应用:来自第3期PaTHway试验3.5年的结果

2026-10-270
OAAI
Efficacy and Safety of Lonapegsomatropin in Children With Turner Syndrome: 52-Week Results From the New InsiGHTS Trial

长效奥曲肽生长激素在特纳综合征儿童中的有效性与安全性:新InsiGHTS试验52周结果

2026-10-260
OAAI
Long-term Safety and Efficacy of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial

成人生长激素缺乏症患者每周一次 Lonapegsomatropin 的长期安全性和有效性:一项 52 周开放标签扩展试验的结果

2026-10-090
OAAI
Navepegritide Combined with Lonapegsomatropin for the Treatment of Children with Achondroplasia: 52-Week Results from the Phase 2 COACH Trial

纳维培利肽与隆肽生长激素联合治疗软骨发育不全儿童:第2期COACH试验52周结果

2026-05-180
OA
Longitudinal Observation of Children with Achondroplasia: Findings from a Global Natural History Study (ACHieve)

对软骨发育不全患儿的纵向观察:全球自然病史研究(ACHieve)的结果

2026-01-010
OA
Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial
2026-01-010
OA
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

每周一次Lonapegsomatropin治疗成人生长激素缺乏症的疗效和安全性: foresiGHt试验结果

2025-12-200
OA
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results

生长激素缺乏的儿童接受Lonapegsomatropin治疗后显示出可持续的身高改善,持续长达6年:enliGHten试验最终结果

2025-03-060
OA
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
2024-10-084
OA
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
2024-04-3012
OAAI
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial

每周一次的travicon CNP (navepegritide) 治疗软骨发育不全儿童 (acimalt): 一项2期,多中心,随机,双盲,安慰剂对照,剂量递增试验

2023-11-014
OAAI
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial
2022-10-2144
OAAI
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
2022-04-1617
OA
Response to Letter to the Editor From Malozowski: Weekly Lonapegsomatropin in Treatment-Naive Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
2021-12-160
OA